8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Mar 2, 2026·SEC
NewAmsterdam Pharma Company N.V.(NAMS)Earnings, Financials & Key Ratios
NAMS•NASDAQ
$35.44
$4.14B mkt cap·Price updated May 15, 2026
AboutNewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.Show more
- Revenue$23M-50.6%
- EBITDA-$225M-28.0%
- Net Income-$204M+15.6%
- EPS (Diluted)-1.75+31.6%
- Gross Margin99.74%-0.3%
- EBITDA Margin-1001.92%-159.1%
- Operating Margin-1002.9%-159.2%
- Net Margin-905.74%-70.8%
- ROE-28.29%+38.8%
- ROIC-188.24%
- Debt/Equity0.00-49.9%
NAMS Key Insights
NewAmsterdam Pharma Company N.V. (NAMS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 96.1% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 21.2% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NAMS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NAMS Price & Volume
NewAmsterdam Pharma Company N.V. (NAMS) stock price & volume — 10-year historical chart
Loading chart...
NAMS Growth Metrics
NewAmsterdam Pharma Company N.V. (NAMS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-39.71%
TTM-52.13%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-13.54%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM5.24%
Return on Capital
10 Years-26%
5 Years-30.25%
3 Years-38.07%
Last Year-31.32%
NAMS Recent Earnings
NewAmsterdam Pharma Company N.V. (NAMS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 6/12 qtrs (67%)
Q2 2026Latest
May 7, 2026EPS
$0.40
Est $0.46
+13.0%
Revenue
$3M
Est $2M
+72.0%
Q1 2026
Feb 18, 2026EPS
$0.63
Est $0.43
-45.1%
Revenue
$32,000
Est $3M
-98.9%
Q4 2025
Nov 5, 2025EPS
$0.41
Est $0.38
-7.9%
Revenue
$348,000
Est $2M
-85.5%
Q3 2025
Aug 6, 2025EPS
$0.15
Est $0.52
+71.2%
Revenue
$22M
Est $3M
+542.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.40vs $0.46+13.0% | $3Mvs $2M+72.0% |
| Q1 2026 | Feb 18, 2026 | $0.63vs $0.43-45.1% | $32,000vs $3M-98.9% |
| Q4 2025 | Nov 5, 2025 | $0.41vs $0.38-7.9% | $348,000vs $2M-85.5% |
| Q3 2025 | Aug 6, 2025 | $0.15vs $0.52+71.2% | $22Mvs $3M+542.0% |
Based on last 12 quarters of dataView full earnings history →
NAMS Peer Comparison
NewAmsterdam Pharma Company N.V. (NAMS) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ESPR | 648.68M | 3.12 | -28.36 | 21.31% | -1.77% | |||
 MDGL | 12.07B | 523.69 | -40.75 | 432.05% | -27.32% | -50.15% | 0.59 | |
 LNTH | 6.11B | 93.91 | 27.54 | 0.5% | 18.05% | 24.33% | 0.00 | |
 PFE | 144.09B | 25.33 | 18.63 | -1.65% | 11.83% | 8.34% | 0.78 | |
 MRK | 275.1B | 111.38 | 15.30 | 1.18% | 28.12% | 36.14% | 0.96 | |
 NVS | 282.55B | 148.08 | 20.60 | 5.97% | 24.14% | 31.42% | 0.80 | |
 AZN | 281.5B | 181.58 | 27.76 | 8.63% | 17.19% | 22.24% | 0.61 | |
 AMGN | 176.1B | 326.31 | 22.93 | 9.92% | 20.95% | 89.41% | 6.31 |
Compare NAMS vs Peers
NewAmsterdam Pharma Company N.V. (NAMS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NAMS Income Statement
NewAmsterdam Pharma Company N.V. (NAMS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 102.69M | 14.09M | 45.56M | 22.5M | 22.57M |
| Revenue Growth % | - | - | - | -86.28% | 223.37% | -50.61% | -52.13% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 59K | 559K |
| COGS % of Revenue | - | - | - | - | - | 0.26% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 102.69M▲ 0% | 14.09M▼ 86.3% | 45.56M▲ 223.4% | 22.44M▼ 50.7% | 22.01M▲ 0% |
| Gross Margin % | - | - | 100% | 100% | 100% | 99.74% | 97.52% |
| Gross Profit Growth % | - | - | - | -86.28% | 223.37% | -50.74% | - |
| Operating Expenses | 6.63M | 34.98M | 106.25M | 197.06M | 221.85M | 248.13M | 237.18M |
| OpEx % of Revenue | - | - | 103.46% | 1398.56% | 486.91% | 1102.64% | - |
| Selling, General & Admin | 1.69M | 5.68M | 19.51M | 37.63M | 70.45M | 106.3M | 102.59M |
| SG&A % of Revenue | - | - | 19% | 267.09% | 154.61% | 472.36% | - |
| Research & Development | 4.94M | 28.97M | 86.74M | 159.42M | 151.41M | 141.83M | 134.59M |
| R&D % of Revenue | - | - | 84.47% | 1131.47% | 332.3% | 630.28% | - |
| Other Operating Expenses | 0 | 326K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -6.63M▲ 0% | -34.98M▼ 427.4% | -3.56M▲ 89.8% | -182.97M▼ 5043.9% | -176.29M▲ 3.6% | -225.68M▼ 28.0% | -215.18M▲ 0% |
| Operating Margin % | - | - | -3.46% | -1298.56% | -386.91% | -1002.9% | -953.59% |
| Operating Income Growth % | - | -427.39% | 89.83% | -5043.86% | 3.65% | -28.02% | - |
| EBITDA | -6.63M | -34.97M | -3.55M | -182.92M | -176.18M | -225.46M | -214.95M |
| EBITDA Margin % | - | - | -3.45% | -1298.21% | -386.66% | -1001.92% | -952.57% |
| EBITDA Growth % | - | -427.41% | 89.85% | -5055.52% | 3.69% | -27.98% | -13.38% |
| D&A (Non-Cash Add-back) | 1.22K | 5K | 9K | 49K | 113K | 220K | 230K |
| EBIT | -6.63M | -41.37M | -22.35M | -176.91M | -241.6M | -242.54M | -232.04M |
| Net Interest Income | 851 | -411K | -287K | 3.42M | 16.88M | 27.59M | 24.28M |
| Interest Income | 851 | 0 | 0 | 10.22M | 16.88M | 27.59M | 24.28M |
| Interest Expense | 0 | 411K | 287K | 6.8M | 0 | 0 | 0 |
| Other Income/Expense | -390.91K | -6.81M | -19.08M | 6.06M | -65.31M | 21.86M | 2.44M |
| Pretax Income | -7.02M▲ 0% | -41.78M▼ 495.0% | -22.63M▲ 45.8% | -176.91M▼ 681.6% | -241.6M▼ 36.6% | -203.82M▲ 15.6% | -212.73M▲ 0% |
| Pretax Margin % | - | - | -22.04% | -1255.57% | -530.25% | -905.74% | -942.76% |
| Income Tax | 0 | 0 | 0 | 27K | -1K | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | -0.02% | 0% | 0% | 0% |
| Net Income | -7.02M▲ 0% | -41.78M▼ 495.0% | -22.63M▲ 45.8% | -176.94M▼ 681.7% | -241.6M▼ 36.5% | -203.82M▲ 15.6% | -212.73M▲ 0% |
| Net Margin % | - | - | -22.04% | -1255.76% | -530.25% | -905.74% | -942.76% |
| Net Income Growth % | - | -494.98% | 45.83% | -681.73% | -36.54% | 15.64% | -13.54% |
| Net Income (Continuing) | -7.02M | -41.78M | -22.63M | -176.94M | -241.6M | -203.82M | -212.73M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.15▲ 0% | -3.34▼ 190.4% | -1.19▲ 64.4% | -2.15▼ 80.7% | -2.56▼ 19.1% | -1.75▲ 31.6% | -1.76▲ 0% |
| EPS Growth % | - | -190.43% | 64.37% | -80.67% | -19.07% | 31.64% | 5.24% |
| EPS (Basic) | -1.15 | -3.34 | -1.19 | -2.15 | -2.56 | -1.75 | - |
| Diluted Shares Outstanding | 17.75M | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M | 121.1M |
| Basic Shares Outstanding | 17.75M | 17.75M | 18.97M | 82.16M | 94.36M | 114.4M | 121.1M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
NAMS Balance Sheet
NewAmsterdam Pharma Company N.V. (NAMS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.87M | 66.96M | 477.98M | 346.79M | 863.41M | 675.7M | 658.04M |
| Cash & Short-Term Investments | 1.37M | 60.38M | 467.73M | 340.45M | 834.19M | 636.24M | 636.11M |
| Cash Only | 1.37M | 60.38M | 467.73M | 340.45M | 771.74M | 490M | 457.61M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 62.45M | 146.24M | 178.5M |
| Accounts Receivable | 0 | 0 | 0 | 1.88M | 21.3M | 23.15M | 0 |
| Days Sales Outstanding | - | - | - | 48.73 | 170.67 | 375.53 | 175.51 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 4.88M | 2.07M | 0 | 0 | 1.32M | 21.94M |
| Total Non-Current Assets | 138M | 1.03M | 518K | 306K | 1.21M | 93.58M | 74.6M |
| Property, Plant & Equipment | 0 | 216.08K | 154K | 101K | 673K | 568K | 400K |
| Fixed Asset Turnover | - | - | 666.84x | 139.50x | 67.70x | 39.62x | 41.85x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 208K | 170K | 534K | 407K | 375K |
| Long-Term Investments | 138M | 0 | 0 | 0 | 0 | 0 | 97.26M |
| Other Non-Current Assets | 0 | 816.56K | 156K | 35K | 0 | 92.61M | 166.43M |
| Total Assets | 139.87M▲ 0% | 67.99M▼ 51.4% | 478.5M▲ 603.8% | 347.1M▼ 27.5% | 864.62M▲ 149.1% | 769.28M▼ 11.0% | 732.64M▲ 0% |
| Asset Turnover | - | - | 0.21x | 0.04x | 0.05x | 0.03x | 0.03x |
| Asset Growth % | - | -51.39% | 603.79% | -27.46% | 149.1% | -11.03% | 140.03% |
| Total Current Liabilities | 236.52K | 11.24M | 36.06M | 49.9M | 106.92M | 85.79M | 67.42M |
| Accounts Payable | 162.48K | 7.07M | 11.85M | 16.92M | 4.74M | 8.97M | 8.09M |
| Days Payables Outstanding | - | - | - | - | - | 55.49K | 4.34K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 246K | 136K | 23K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 8.94M | 6.01M | 3.99M | 7.97M |
| Other Current Liabilities | 74.04K | 0 | 18.02M | 15.96M | 91.03M | 72.69M | 55.32M |
| Current Ratio | 7.90x | 5.96x | 13.26x | 6.95x | 8.08x | 7.88x | 7.88x |
| Quick Ratio | 7.90x | 5.96x | 13.26x | 6.95x | 8.08x | 7.88x | 7.88x |
| Cash Conversion Cycle | - | - | - | - | - | - | -4.16K |
| Total Non-Current Liabilities | 12.17M | 126.24K | 12.37M | 8.81M | 202K | 66K | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 66K | 0 |
| Capital Lease Obligations | 0 | 126.24K | 60K | 0 | 202K | 0 | 103K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 12.17M | 0 | 12.31M | 7.79M | 0 | 0 | 0 |
| Total Liabilities | 12.41M | 11.36M | 48.43M | 58.7M | 107.12M | 85.85M | 67.42M |
| Total Debt | 0 | 186.51K | 126K | 60K | 448K | 202K | 23K |
| Net Debt | -1.37M | -60.19M | -467.6M | -340.39M | -771.29M | -489.8M | -457.58M |
| Debt / Equity | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | 2.13x |
| Interest Coverage | - | -100.67x | -77.86x | -26.02x | - | - | - |
| Total Equity | 127.46M▲ 0% | 56.63M▼ 55.6% | 430.07M▲ 659.5% | 288.39M▼ 32.9% | 757.5M▲ 162.7% | 683.43M▼ 9.8% | 665.22M▲ 0% |
| Equity Growth % | - | -55.57% | 659.49% | -32.94% | 162.66% | -9.78% | 168.9% |
| Book Value per Share | 7.18 | 3.19 | 22.68 | 3.51 | 8.03 | 5.97 | 5.49 |
| Total Shareholders' Equity | 127.46M | 56.63M | 430.07M | 288.39M | 757.5M | 683.43M | 665.22M |
| Common Stock | 122.46M | 128.51K | 10.05M | 10.17M | 13.44M | 14.28M | 14.59M |
| Retained Earnings | 41.45K | -39.44M | -140.04M | -316.97M | 0 | -762.39M | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 672.13K | 4.42M | 4.42M | 4.47M | 4.79M | 4.22M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NAMS Cash Flow Statement
NewAmsterdam Pharma Company N.V. (NAMS) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.34M | -29.51M | 10.66M | -141.22M | -158.56M | -147.78M | -147.78M |
| Operating CF Margin % | - | - | 10.39% | -1002.26% | -348.01% | -656.73% | - |
| Operating CF Growth % | - | -301.92% | 136.14% | -1424.13% | -12.28% | 6.8% | -124.87% |
| Net Income | -7.07M | -41.78M | -22.63M | -176.94M | -241.6M | 0 | -212.73M |
| Depreciation & Amortization | 1.23K | 5K | 9K | 49K | 113K | 220K | 230K |
| Stock-Based Compensation | 0 | 1.24M | 4.12M | 24.57M | 33.62M | 59.42M | 30.19M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 376.37K | 6.55M | 18.8M | 5.23M | 81.98M | -199.48M | -62.97M |
| Working Capital Changes | -649.41K | 4.47M | 10.37M | 5.87M | -32.67M | -7.94M | -25.53M |
| Change in Receivables | 0 | 0 | -4.18M | 4.03M | 0 | -13.28M | 5.16M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 6.56M | 4.81M | 5.07M | -12.95M | 4.91M | 1.86M |
| Cash from Investing | -15.99K | -24K | -221K | -24K | -62.85M | -174.92M | -189.28M |
| Capital Expenditures | -15.99K | -24K | -221K | -24K | -672K | -246K | -268K |
| CapEx % of Revenue | - | - | 0.22% | 0.17% | 1.47% | 1.09% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 13.92M | 84.7M | 391.9M | 8.91M | 659.51M | 29.52M | 34.07M |
| Debt Issued (Net) | 13.92M | 0 | 747K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 84.7M | 396.95M | 8.91M | 645.51M | 29.52M | 34.07M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -5.79M | 0 | 14M | 0 | 0 |
| Net Change in Cash | 6.59M▲ 0% | 50.48M▲ 665.6% | 407.6M▲ 707.4% | -127.28M▼ 131.2% | 431.29M▲ 438.9% | -280.42M▼ 165.0% | -289.48M▲ 0% |
| Free Cash Flow | -7.36M▲ 0% | -29.54M▼ 301.4% | 10.44M▲ 135.4% | -141.24M▼ 1452.4% | -159.24M▼ 12.7% | -148.03M▲ 7.0% | -142.19M▲ 0% |
| FCF Margin % | - | - | 10.17% | -1002.43% | -349.49% | -657.82% | -630.12% |
| FCF Growth % | - | -301.37% | 135.36% | -1452.37% | -12.74% | 7.04% | -1.03% |
| FCF per Share | -0.41 | -1.66 | 0.55 | -1.72 | -1.69 | -1.29 | -1.29 |
| FCF Conversion (FCF/Net Income) | 1.05x | 0.71x | -0.47x | 0.80x | 0.66x | 0.73x | 0.67x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 1K | 0 | 0 |
NAMS Key Ratios
NewAmsterdam Pharma Company N.V. (NAMS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -45.4% | -9.3% | -49.25% | -46.2% | -28.29% | -29.8% |
| Return on Invested Capital (ROIC) | -42.82% | - | - | - | -188.24% | -188.24% |
| Gross Margin | - | 100% | 100% | 100% | 99.74% | 97.52% |
| Net Margin | - | -22.04% | -1255.76% | -530.25% | -905.74% | -942.76% |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Interest Coverage | -100.67x | -77.86x | -26.02x | - | - | - |
| FCF Conversion | 0.71x | -0.47x | 0.80x | 0.66x | 0.73x | 0.67x |
| Revenue Growth | - | - | -86.28% | 223.37% | -50.61% | -52.13% |
NAMS SEC Filings & Documents
NewAmsterdam Pharma Company N.V. (NAMS) SEC filings — annual & quarterly reports (10-K, 10-Q)
NAMS Frequently Asked Questions
NewAmsterdam Pharma Company N.V. (NAMS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NewAmsterdam Pharma Company N.V. (NAMS) reported $22.6M in revenue for fiscal year 2025.
NewAmsterdam Pharma Company N.V. (NAMS) saw revenue decline by 50.6% over the past year.
NewAmsterdam Pharma Company N.V. (NAMS) reported a net loss of $212.7M for fiscal year 2025.
Dividend & Returns
NewAmsterdam Pharma Company N.V. (NAMS) has a return on equity (ROE) of -28.3%. Negative ROE indicates the company is unprofitable.
NewAmsterdam Pharma Company N.V. (NAMS) had negative free cash flow of $142.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More NAMS
NewAmsterdam Pharma Company N.V. (NAMS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates